Skip to content
Screener

Investing Cash Flow at other companies

Schrodinger logo
SchrodingerSDGR
$58.62M+205%
Absci Corporation logo
Absci CorporationABSI
$7.36M+149%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-$25.08M-416%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
-$353.03M-570%
Septerna, Inc. logo
Septerna, Inc.SEPN
-$23.82M-389%
Xencor logo
XencorXNCR
$85.12M+110%

Other financials

Income statement

See full
Revenue$7.7M-60.1%
Gross profit-$3.8M-307%
Operating income-$135.0M+23.4%
Net income-$131.0M+23.8%
EPS (diluted)-$0.25+39.0%

Balance sheet

See full
Cash & equivalents$556.8M+4.3%
Total debt$80.5M-27.2%
Total equity$915.0M-0.5%
Total assets$1.2B-6.9%

Cash flow

See full
Operating cash flow-$105.9M-38.6%
CapEx$44.0K-98.6%
Free cash flow-$106.0M-33.2%

Valuation

See full
Market cap$1.7B-28.6%
Enterprise value$1.22B-37.5%
P/S31×-5.9×

Profitability

See full
Gross margin3.5%
Operating margin-991.7%-13.7pp
Net margin-945.9%-52.4pp
FCF margin-642.2%+36.1pp

Returns & leverage

See full
Return on equity-56.6%-14.5pp
Debt / equity0.1×0.0×
Current ratio+1.5×

Where this comes from

Reported directly by Recursion Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 6:32 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001601830-26-000098
Line itemSix months ended June 30, 2026Six months ended June 30, 2025
Purchase of an intangible asset(1,995)(2,158)
Decrease in cash related to disposal of a business(4,438)
Purchases of investments(1,500)
Net cash used in investing activities(2,297)(13,078)
Cash flows from financing activities
Proceeds from issuance of common shares, net of issuance costs141,024
Equity incentive plans(278)4,293
Repayment of long-term debt and finance lease liabilities(4,459)(4,131)

Item 1. Financial Statements (unaudited)

FAQ

What is Recursion Pharmaceuticals, Inc.'s investing cash flow?
Recursion Pharmaceuticals, Inc. (RXRX) reported investing cash flow of -$1.96M in Q2 2026.
How has Recursion Pharmaceuticals, Inc.'s investing cash flow changed year-over-year?
Recursion Pharmaceuticals, Inc.'s investing cash flow increased by 66.3% year-over-year, from -$5.81M to -$1.96M.
What is the long-term trend for Recursion Pharmaceuticals, Inc.'s investing cash flow?
Over 4 years (2021 to 2025), Recursion Pharmaceuticals, Inc.'s investing cash flow has grown at a -50.1% compound annual growth rate (CAGR), from -$271.74M to -$16.87M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Ask your AI about Recursion Pharmaceuticals, Inc.'s investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude